Evaluation of Multiple-Flows Exhaled Nitric Oxide and Its Clinical Significance in Severe Asthmatic Patients Treated with Biologics: A Prospective Real-Life Study

Specific biomarkers, such as eosinophilia in peripheral blood or fractional exhaled nitric oxide (FeNO), can guide us in the choice of biologic therapy, allowing a more personalized approach. Although there are multiple evidences in the literature about the role of FeNO as a predictor of response to different biologic treatments, there are no data on the relationship between FeNO changes and clinical response to the four biologic drugs currently in use.